Anixa Bio rises on U.S. patent for cancer vaccine

Anixa Biosciences

27/02/2023 15:49

** Shares of vaccine and therapy developer Anixa Biosciences
Inc  ANIX.O  rise 3.1% to $4.1 in morning trade 
    ** Co says it has been granted an additional U.S. patent
covering its experimental cancer vaccine being tested to prevent
a type of breast cancer
    ** The patent titled, "Vaccine Adjuvants and Formulations",
covers additional intellectual property related to the
formulation of the vaccine -ANIX
    ** Co has exclusive global license to the vaccine,
originally developed at Cleveland Clinic -ANIX
    ** Including session moves, stock has risen ~50.5% in the
past 12 months

 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))